Skip to content

US · RNAC · BIOTECHNOLOGY

Cartesian Therapeutics, Inc. (RNAC) intrinsic value and stock valuation

$6.14as of 2026-11-21 · Mkt cap 245.34M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cartesian Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values RNAC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RNAC’s statements →

Cartesian Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Frederick, MD 21703 cartesiantherapeutics.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$2.8M-29.9% 5y CAGRd
20142025
Net income
-$-130.3M
20142025
Free cash flow
-$-79.39M
20142025
Total equity
-$-126.24M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$2.8M$38.9M$26M$110.8M$85.1M
Operating income-$-86.7M-$-43.9M-$-86.42M$14.5M-$-4.6M
Net income-$-130.3M-$-77.42M-$-219.71M$35.4M-$-25.69M
EPSd-$-5.02M-$-3.27M-$-42.5M$8.74M-$-8.08M
Operating cash flow-$-73.94M-$-23.67M-$-51.16M-$-31.63M-$-60.38M
Capital expenditure-$-5.45M-$-9.09M-$-210K-$-1.2M-$-1.08M
Free cash flow-$-79.39M-$-32.77M-$-51.37M-$-32.83M-$-61.47M
Total assets$296.4M$435M$305.1M$165.9M$159.9M
Total debt$12.7M$14M$11M$37.9M$35.3M
Net debt-$-112.46M-$-198.63M-$-65.96M-$-68.51M-$-78.78M
Total equity-$-126.24M-$-6.8M-$-440.18M$93.8M$22.5M
Cash and short-term investments$125.1M$212.6M$76.9M$134.6M$128.1M
Income statement
20252024202320222021
Revenue$2.8M$38.9M$26M$110.8M$85.1M
Cost of revenue$0.00$0.00$0.00$2.04M$0.00
Gross profit$2.8M$38.9M$26M$108.7M$85.1M
Research and development expenses$58M$45.1M$71.3M$72.4M$68.7M
Selling, general and administrative expenses$31.5M$30.1M$40.5M$23.9M$20.9M
Other expenses$0.00$7.58M$710K-$-2.04M$0.00
Operating expenses$89.5M$82.8M$112.4M$94.2M$89.7M
Cost and expenses$89.5M$82.8M$112.4M$96.2M$89.7M
Interest income$6.58M$7.39M$4.96M$0.00$0.00
Interest expense$0.00$0.00$2.83M$3.03M$2.84M
Depreciation and amortization$2.96M$1.15M$840K$2.04M$1.72M
Ebitda-$-136.54M-$-75.99M-$-235.03M$39.8M-$-5.16M
Operating income-$-86.7M-$-43.9M-$-86.42M$14.5M-$-4.6M
Total other income/expenses, net-$-52.79M-$-33.24M-$-152.29M$20.2M-$-5.12M
Income before tax-$-139.5M-$-77.14M-$-238.71M$34.8M-$-9.72M
Income tax expense-$-9.19M$290K-$-19M-$-610K$16M
Net income-$-130.3M-$-77.42M-$-219.71M$35.4M-$-25.69M
Weighted average shares outstanding$26M$25.9M$5.17M$4.02M$3.18M
Weighted average diluted shares outstanding$26M$23.7M$5.17M$4.05M$3.18M
Balance sheet
20252024202320222021
Cash and short-term investments$125.1M$212.6M$76.9M$134.6M$128.1M
Net receivables$1.11M$870K$8.85M$9.86M$9.91M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$129.3M$216.6M$90.7M$148.1M$144.4M
Property, plant and equipment, net$17.8M$15.5M$12.2M$14.4M$12M
Goodwill and intangible assets$48.2M$198.8M$198.8M$0.00$0.00
Long-term investments$1.74M$2M$2M$2M$2M
Total non-current assets$167.1M$218.4M$214.3M$17.8M$15.4M
Total assets$296.4M$435M$305.1M$165.9M$159.9M
Accounts payable$1.29M$290K$3.15M$320K$220K
Short-term debt$4.15M$2.85M$2.17M$10.1M$7.01M
Deferred revenue$0.00$0.00$2.31M$590K$53.9M
Total current liabilities$14.9M$23M$68.2M$25.1M$72.3M
Long-term debt$8.53M$11.1M$8.79M$27.8M$28.3M
Deferred revenue, non-current$0.00$0.00$3.54M$0.00$11.4M
Total non-current liabilities$407.7M$418.9M$677M$47M$65.1M
Capital lease obligations$8.53M$14M$11M$11.7M$9.65M
Total liabilities$422.7M$441.8M$745.2M$72.1M$137.4M
Common stock$0.00$0.00$20K$10K$10K
Retained earnings-$-822.37M-$-692.07M-$-614.65M-$-394.94M-$-430.32M
Accumulated other comprehensive income (loss)-$-4.58M-$-4.62M-$-4.6M-$-4.56M-$-4.57M
Total equity-$-126.24M-$-6.8M-$-440.18M$93.8M$22.5M
Total investments$1.74M$2M$2M$30.2M$16M
Total debt$12.7M$14M$11M$37.9M$35.3M
Net debt-$-112.46M-$-198.63M-$-65.96M-$-68.51M-$-78.78M
Cash flow statement
20252024202320222021
Net income-$-130.3M-$-77.42M-$-219.71M$35.4M-$-25.69M
Depreciation and amortization$2.96M$1.15M$840K$1.29M$1.25M
Stock-based compensation$10.5M$6.58M$22.5M$11.2M$7.72M
Change in working capital-$-8.06M-$-5.79M$4.97M-$-60.38M-$-48.19M
Accounts receivable-$-240K$7.98M$910K$3.32M-$-2.69M
Inventory$0.00$0.00$0.00$920K$210K
Accounts payable$1.07M-$-2.93M$2.83M$90K-$-220K
Net cash provided by operating activities-$-73.94M-$-23.67M-$-51.16M-$-31.63M-$-60.38M
Investments in property, plant and equipment-$-5.45M-$-9.09M-$-210K-$-1.2M-$-1.08M
Acquisitions, net$0.00$350K$6.56M$0.00$0.00
Net cash used for investing activities-$-5.45M-$-8.74M$34.6M-$-15M-$-17.14M
Common stock issued-$-300K$124.4M$0.00$39M$52M
Common stock repurchased$0.00$0.00-$-6.17M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-8.05M$168.4M-$-13.14M$39.2M$52.9M
Net change in cash-$-87.41M$136M-$-29.75M-$-7.4M-$-24.63M
Cash at end of period$126.9M$214.3M$78.3M$108M$115.4M
Operating cash flow-$-73.94M-$-23.67M-$-51.16M-$-31.63M-$-60.38M
Capital expenditure-$-5.45M-$-9.09M-$-210K-$-1.2M-$-1.08M
Free cash flow-$-79.39M-$-32.77M-$-51.37M-$-32.83M-$-61.47M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cartesian Therapeutics, Inc.

        Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

        CEO
        Carsten Brunn
        Employees
        75
        Beta
        0.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Cartesian Therapeutics, Inc. (RNAC)?

        Cartesian Therapeutics, Inc. (RNAC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RNAC undervalued?

        RNAC trades at a price of $6.14 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.